KAWASAKI, Japan, April 30, 2024--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter "PeptiDream") (Tokyo: 4587) today announced an expansion of its peptide discovery collaboration with Swiss-based Novartis Pharma AG ("hereinafter Novartis") (NYSE: NVS). Under the multi-program agreement, PeptiDream will use its proprietary Peptide Discovery Platform System ("PDPS®") technology to identify and optimize novel macrocyclic pepti
KAWASAKI, Japan, September 20, 2023--Combining the PeptiDream's expertise in the field of peptide-RI conjugates, with Genentech's powerful development and commercialization capabilities.
TOKYO & KAWASAKI, Japan, July 25, 2023--PeptiDream and Astellas plan to combine PeptiDream's peptide discovery technology with Astellas' capabilities to discover next-gen protein degraders.